CDTX Share Price Performance
US$217.71
203.34 (1,415.03%)
12.9% undervalued intrinsic discount
US$250.00
Fair Value
Price US$217.71
birdflustocks US$250.00
Fair ValueUS$100.00
Share Pricen/a
Cidara Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 42 Fair Values set on narratives written by author
CDTX Community Narratives
BI
Fair Value US$100 117.7% overvalued intrinsic discount
Cidara Therapeutics: The underestimated potential of CD388
9users have liked this narrative
0users have commented on this narrative
35users have followed this narrative
Cidara Therapeutics: The underestimated potential of CD388
Summary CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.Read more
9users have liked this narrative
0users have commented on this narrative
35users have followed this narrative
BI
US$100
117.7% overvalued intrinsic discount
birdflustocks Fair Value
Revenue growth
83.73% p.a.
Profit Margin
19.58%
Future PE
26.11x
Share price in 2035
US$7.22k
Snowflake Analysis
Cidara Therapeutics, Inc. Key Details
About CDTX
- Founded
- 2012
- Employees
- 38
- CEO
- WebsiteView website
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
